Kurabo Industries has agreed to buy 21.6mn shares of diagnostics maker TAUNS Laboratories, equal to 20.27% of voting rights, in an off-market deal at ¥600 a share. TAUNS puts the total at ¥12.96bn. Kurabo's own notice lists an acquisition price of ¥13.34bn and does not explain the gap. Settlement is planned for November 30.
Who sells, who ends up where
Trustar Capital Japan Partners III, L.P. sells 16,299,580 shares, its co-investment vehicle TCJP III Co-Investment, L.P. sells 100,420, and TAUNS's president sells 5,200,000. After the transfer, TAUNS expects its president to be the largest holder at 24.43%, down from 29.31%. Trustar would hold 23.85%, down from 39.14%, and Kurabo 20.27%, third by TAUNS's estimate from the June 30 register. Trustar cuts its stake but stays a major shareholder.
What Kurabo gets beyond shares
TAUNS will put one Kurabo-nominated director to an extraordinary shareholder meeting for election by the end of March 2027 at the latest, and repeat the process at annual meetings while Kurabo holds at least 15% of voting rights. TAUNS also needs Kurabo's prior consent to issue shares that would push Kurabo below 15%, to dispose of certain key intellectual property, and to pursue its own delisting. Kurabo may not unreasonably refuse consent. Reorganisations, large capital spending or financing, and major litigation require prior consultation, and TAUNS may proceed on its own judgment if consultation is not settled within a reasonable period. Kurabo has also agreed to respect TAUNS's management independence, and TAUNS rates the governance impact as minor.
Conditions
Kurabo says the purchase and alliance depend on merger-review clearance and could be brought forward if the conditions are met early. Kurabo expects TAUNS to become an equity-method affiliate and is still assessing the effect on its year to March 2027. The commercial side is less settled: joint research, product development, sales cooperation and staff exchanges are listed, but details are left for later talks.